A peer navigation intervention to prevent HIV among mixed immigrant status Latinx GBMSM and transgender women in the United States: outcomes, perspectives and implications for PrEP uptake

Abstract The Latinx population in the United States is disproportionately affected by HIV. Our community-based participatory research partnership developed, implemented and evaluated a Spanish-language peer navigation intervention designed to increase HIV testing and condom use among social networks of immigrant Spanish-speaking Latinx gay, bisexual and other men who have sex with men (GBMSM) and transgender women (TW). We randomized 21 social networks of Latinx GBMSM and TW, ages 18–55 years, to the intervention, known as HOLA, or a waitlist control group. Social network participants (n = 166) completed structured assessments at baseline and 12-month follow-up (24 months after baseline). Follow-up retention was 95%. Individual in-depth interviews with a sample of participants documented their intervention-related experiences, needs, and priorities to inform future research. At follow-up, HOLA participants reported increased HIV testing (adjusted odds ratio = 8.3; 95% CI = 3.0–23.0; P < 0.0001). All study participants reported increased condom use; there was no significant difference between HOLA and waitlist control participants. In-depth interviews identified critical intervention elements and impacts and community needs and priorities. The HOLA intervention is effective for increasing HIV testing among Latinx GBMSM and TW, an initial step within the HIV prevention and care continua, and may be adaptable to promote pre-exposure prophylaxis uptake.

Download Full-text

Sexual Health of Rural and Urban Young Male Couples in the United States: Differences in HIV Testing, Pre-exposure Prophylaxis Use, and Condom Use

AIDS and Behavior ◽

10.1007/s10461-020-02961-8 ◽

2020 ◽

Cited By ~ 1

Author(s):

Elissa L. Sarno ◽

Emily Bettin ◽

Kyle Jozsa ◽

Michael E. Newcomb

Keyword(s):

United States ◽

Sexual Health ◽

Condom Use ◽

Hiv Testing ◽

Young Male ◽

The United States ◽

Male Couples ◽

Rural And Urban ◽

Exposure Prophylaxis

Download Full-text

Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States

Clinical Infectious Diseases ◽

10.1093/cid/ciz786 ◽

2019 ◽

Vol 71 (1) ◽

pp. 53-62 ◽

Cited By ~ 3

Author(s):

Gloria H Hong ◽

Ana M Ortega-Villa ◽

Sally Hunsberger ◽

Ploenchan Chetchotisakd ◽

Siriluck Anunnatsiri ◽

...

Keyword(s):

United States ◽

Natural History ◽

The United States ◽

Interferon Γ ◽

Mycobacterium Abscessus ◽

Annual Data ◽

Persistent Infections ◽

Ifn Γ ◽

Immunodeficiency Syndrome

Abstract Background The natural history of anti-interferon-γ (IFN-γ) autoantibody-associated immunodeficiency syndrome is not well understood. Methods Data of 74 patients with anti-IFN-γ autoantibodies at Srinagarind Hospital, Thailand, were collected annually (median follow-up duration, 7.5 years). Annual data for 19 patients and initial data for 4 patients with anti-IFN-γ autoantibodies at the US National Institutes of Health were collected (median follow-up duration, 4.5 years). Anti-IFN-γ autoantibody levels were measured in plasma samples. Results Ninety-one percent of US patients were of Southeast Asian descent; there was a stronger female predominance (91%) in US than Thai (64%) patients. Mycobacterium abscessus (34%) and Mycobacterium avium complex (83%) were the most common nontuberculous mycobacteria in Thailand and the United States, respectively. Skin infections were more common in Thailand (P = .001), whereas bone (P < .0001), lung (P = .002), and central nervous system (P = .03) infections were more common in the United States. Twenty-four percent of Thai patients died, most from infections. None of the 19 US patients with follow-up data died. Anti-IFN-γ autoantibody levels decreased over time in Thailand (P < .001) and the United States (P = .017), with either cyclophosphamide (P = .01) or rituximab therapy (P = .001). Conclusions Patients with anti-IFN-γ autoantibodies in Thailand and the United States had distinct demographic and clinical features. While titers generally decreased with time, anti-IFN-γ autoantibody disease had a chronic clinical course with persistent infections and death. Close long-term surveillance for new infections is recommended.

Download Full-text

Learning About HIV: Predicting the Sources of Knowledge That Matter Regarding HIV Testing Among a National Sample of Black and Latinx Adolescents and Young Adults in the United States

Journal of the Association of Nurses in AIDS Care ◽

10.1097/jnc.0000000000000159 ◽

2020 ◽

Vol 31 (4) ◽

pp. 417-427 ◽

Cited By ~ 1

Author(s):

Donte Boyd ◽

Charles Lea ◽

Camille Quinn

Keyword(s):

United States ◽

Young Adults ◽

Hiv Testing ◽

The United States ◽

National Sample ◽

Adolescents And Young Adults ◽

Sources Of Knowledge ◽

Latinx Adolescents

Download Full-text

SAT0172 UTILIZATION OF HYDROXYCHLOROQUINE AND CORTICOSTEROIDS AMONG LUPUS PATIENTS WITH INCIDENT END-STAGE RENAL DISEASE (ESRD) ONSET: A LONGITUDINAL STUDY USING USRDS REGISTRY

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.5103 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1027.2-1027

Author(s):

A. R. Broder ◽

W. Mowrey ◽

A. Valle ◽

B. Goilav ◽

K. Yoshida ◽

...

Keyword(s):

United States ◽

Lupus Nephritis ◽

Renal Disease ◽

International Classification Of Diseases ◽

The United States ◽

Diagnostic Code ◽

Prescribing Practices ◽

Part D ◽

Stage Renal Disease

Background:The development of ESRD due to lupus nephritis is one of the most common and serious complications of SLE. Mortality among SLE ESRD patients is 4-fold higher compared to lupus nephritis patients with preserved renal function1Mortality in SLE ESRD is also twice as high compared with non-SLE ESRD, even though SLE patients develop ESRD at a significantly younger age. In the absence of ESRD specific guidelines, medication utilization in SLE ESRD is unknown.Objectives:The objective of this study was to investigate the real-world current US-wide patterns of medication prescribing among lupus nephritis patients with new onset ESRD enrolled in the United States Renal Disease Systems (USRDS) registry. We specifically focused on HCQ and corticosteroids (CS) as the most used medications to treat SLE.Methods:Inclusion: USRDS patients 18 years and above with SLE as a primary cause of ESRD (International Classification of Diseases, 9thRevision (ICD9) diagnostic code 710.0, previously validated2). who developed ESRD between January 1st, 2006 and July 31, 2011 (to ensure at least 6 months of follow-up in the USRDS). Patients had to be enrolled in Medicare Part D (to capture pharmacy claims). The last follow-up date was defined as either the last date of continuous part D coverage or the end of the study period, Dec 31, 2013.Results:Of the 2579 patients included, 1708 (66%) were HCQ- at baseline, and 871 (34%) were HCQ+ at baseline. HCQ+ patients at baseline had a slightly lower duration of follow-up compared to HCQ- patients at baseline, median (IQR) of 2.32 (1.33, 3.97) years and 2.55 (1.44, 4.25) years, respectively, p= 0.02. During follow-up period, only 778 (30%) continued HCQ either intermittently or continuously to the last follow-up date, 1306 (51%) were never prescribed HCQ after baseline, and 495 (19%) discontinued HCQ before the last follow-up date. Of the 1801 patients who were either never prescribed or discontinued HCQ early after ESRD onset, 713 (40%) were prescribed CS to the end of the follow-up period: 55% were receiving a low dose <10mg/daily, and 43 were receiving moderate dose (10-20mg daily)Conclusion:HCQ may be underprescribed and CS may be overprescribed in SLE ESRD. Changing the current prescribing practices may improve outcomes in SLE ESRDReferences:[1]Yap DY et al., NDT 2012.[2]Broder A et al., AC&R 2016.Acknowledgments :The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.Funding: :NIH/NIAMS K23 AR068441 (A Broder), NIH/NIAMS R01 AR 057327 and K24 AR 066109 (KH Costenbader)Disclosure of Interests: :Anna R. Broder: None declared, Wenzhu Mowrey: None declared, Anna Valle: None declared, Beatrice Goilav: None declared, Kazuki Yoshida: None declared, Karen Costenbader Grant/research support from: Merck, Consultant of: Astra-Zeneca

Download Full-text

Results from the United States CTEPH Registry (US-CTEPH-R): Enrollment Characteristics and 1-Year Follow-up

CHEST Journal ◽

10.1016/j.chest.2021.05.052 ◽

2021 ◽

Author(s):

Kim M. Kerr ◽

C. Greg Elliott ◽

Kelly Chin ◽

Raymond L. Benza ◽

Richard N. Channick ◽

...

Keyword(s):

United States ◽

The United States

Download Full-text

PDG20 Cost-effectiveness of Nivolumab in Patients with Pre-treated Advanced Renal Cell Carcinoma (aRCC) in the United States: Impact of >5 Years of Follow-up Data from Checkmate 025

Value in Health ◽

10.1016/j.jval.2020.08.703 ◽

2020 ◽

Vol 23 ◽

pp. S524

Author(s):

J. May ◽

B. Malcolm ◽

F. Ejzykowicz ◽

M. Kurt ◽

J. Borrill ◽

...

Keyword(s):

United States ◽

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

The United States ◽

Advanced Renal Cell Carcinoma

Download Full-text

Short-term follow-up systems for positive newborn screens in the Washington Metropolitan Area and the United States

Molecular Genetics and Metabolism ◽

10.1016/j.ymgme.2015.11.002 ◽

2015 ◽

Vol 116 (4) ◽

pp. 226-230 ◽

Cited By ~ 1

Author(s):

Sarah Viall ◽

Sneha Jain ◽

Kimberly Chapman ◽

Nicholas Ah Mew ◽

Marshall Summar ◽

...

Keyword(s):

United States ◽

Metropolitan Area ◽

The United States ◽

Short Term

Download Full-text

Increased Early Revision Rate with the INFINITY Total Ankle Prosthesis

Foot & Ankle Orthopaedics ◽

10.1177/2473011418s00037 ◽

2018 ◽

Vol 3 (3) ◽

pp. 2473011418S0003

Author(s):

Elizabeth Cody ◽

Michel Taylor ◽

James Nunley ◽

Selene Parekh ◽

James DeOrio

Keyword(s):

United States ◽

Tibial Component ◽

Revision Rate ◽

The United States ◽

Additional Patient ◽

Foot And Ankle ◽

Early Revision ◽

One Year ◽

Component Loosening

Category: Ankle Arthritis Introduction/Purpose: Modern total ankle arthroplasties (TAAs) have demonstrated improved survival rates at early- and mid-term follow-up, with revision rates ranging from 4 to 8% at five years. The INFINITY total ankle system (Wright Medical Technology, Arlington, TN) was first used in the United States in 2014. Its advantages include the ability to use patient-specific instrumentation and the option to choose between talar dome resurfacing and flat-cut talar components. While this implant is currently popular in the United States, clinical outcomes have not yet been reported. Our aim was to identify the rate of early revision among patients receiving the INFINITY prosthesis. Methods: Patients from two prospectively-collected databases at the authors’ institution were screened for inclusion in the present study. All patients who underwent a primary TAA with the INFINITY prosthesis and who were at least one year postoperative were included. All surgeries were performed by one of two orthopaedic foot and ankle surgeons with extensive experience in total ankle arthroplasty. The primary outcome was the need for revision surgery, which was defined as removal of one or both metal components. Peri-implant lucency at most recent follow-up was a secondary outcome. Anteroposterior and lateral radiographs at most recent follow-up were graded for lucency independently by two reviewers, both orthopaedic foot and ankle fellows, for individual peri-implant zones (Figure). Each zone was only considered “lucent” if recorded as such by both reviewers. Results: 160 patients underwent TAA with the INFINITY prosthesis between August 2014 and November 2016 with a mean 20 months of follow-up (range, 12-37). Six patients were lost to follow-up. Sixteen patients (10%) underwent revision a mean 1.2 years postoperatively. Revision was performed most commonly for tibial component loosening (seven patients, 4.4%) and deep infection (five patients, 3.1%). Of cases with tibial loosening, progressive lucency and/or subsidence was obvious radiographically in four patients; one patient had equivocal radiographs but loosening was suggested on single-photon emission computed tomography; and two patients revised for persistent pain had loosening confirmed intraoperatively. Of the 108 patients with retained components and at least one year of radiographic follow-up, eight (7.4%) had global lucency around the tibial component at most recent follow-up. Conclusion: Our initial review of patients undergoing TAA with the INFINITY prosthesis demonstrates an elevated early revision rate due to tibial component loosening. The reasons for this finding remain unclear, but could possibly include inadequate bony purchase of the implant’s three prongs, particularly in patients with large preoperative deformities or with imperfect component alignment. We plan to further investigate the possible reasons for this finding in the future by assessing additional patient factors, including age, sex, arthritis type, tobacco use, pre- and postoperative coronal and sagittal alignment, and presence of ipsilateral hindfoot fusion.

Download Full-text